CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
To assess the effectiveness, safety, and tolerability of using nivolumab in patients with Small Cell Lung Cancer (SCLC). This study will also compare any good and bad effects of adding a drug called ipilimumab to using nivolumab to see if it improves the survival of patients with SCLC, and if it can delay the progression of lung cancer when compared to placebo.
Extensive-stage disease Small Cell Lung Cancer (SCLC)
1. Male or female age 18 or older
2. Confirmed Small Cell Lung Cancer (SCLC)
3. Extensive stage disease (Stage IV)
4. Received one prior chemotherapy for metastatic disease
Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be followed until the end of the study.
Knight Clinical Trials Information Line